
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Hldgs is well-positioned for success with its innovative RaniPill capsule technology, which has the potential to revolutionize the delivery of biologic drugs. The company's pipeline of programs in obesity, osteoporosis, psoriasis, and psoriatic arthritis addresses target markets with significant unmet needs and potential for high margins. However, the company faces regulatory risk, as the FDA may refuse to approve an IDE for the RaniPill or require additional studies, and the political and regulatory landscape may change unfavorably.
Bears say
Rani Therapeutics Hldgs is a clinical-stage biotherapeutics company with a negative outlook due to potential clinical and commercial risks. While the RaniPill technology has the potential to provide a convenient alternative to painful injections, there is a risk that the safety and efficacy data may not replicate in larger studies. In addition, the company's reliance on generic or biosimilar APIs may limit market share and lead to competition from other long-acting injectable or oral delivery technologies. The recent capital raise has also increased the number of fully diluted shares, leading to a decrease in the 12-month price target.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares